Discrimination of hepatocyte-stimulating activity from human recombinant tumor necrosis factor alpha by Andus, T. et al.
Eur. J. Immunol. 1987.17: 1193-1197 Hepatocyte-stimulating factor is different from TNFa 1193 
Tilo Andus', 
Peter C. Heinrich', 
Joachim Bauer*, 
Thuy-Anh Tran-Thi', 
Karl Decker', 
Daniela Mannel' and 
Hinnak Northow 
Biochemisches Institut', Universitat 
Freiburg, Freiburg, Medizinische 
Universitatsklinik*, Freiburg, DKFZ, 
Institut fur Immunologie und Genetik', 
Heidelberg and Blutspendezentrale des 
DRK+, UIm 
Discrimination of hepatocyte-stimulating activity from 
human recombinant tumor necrosis factor a* 
The involvement of tumor necrosis factor a (TNFa) in the regulation of acute-phase 
protein synthesis is currently under discussion.In this study the effect of human 
recombinant TNFa on the regulation of the 4 acute-phase proteins a2-macroglobulin, 
albumin, al-proteinase inhibitor and al-acute-phase globulin was investigated in rat 
hepatocyte primary cultures. No changes in synthesis of any of the 4 proteins were 
observed. However, an acute-phase response similar to that in vivo could be gener- 
ated by conditioned media from human monocytes containing natural TNFa. This 
response remained unchanged after neutralizing TNFa activity by the addition of a 
specific antibody to TNFa. It is concluded that the hepatocyte-stimulating activity 
synthesized by human monocytes is different from TNFa. 
1 Introduction 
Injuries such as bacterial or parasitic infections, physical and 
chemical traumata, malignant tumors and immunologic disor- 
ders lead to a highly complex reaction of the organism, the so- 
called acute-phase response [l-31. The acute-phase response is 
characterized by fever, leukocytosis, a negative nitrogen 
balance and an increase in the synthesis of hepatic acute-phase 
proteins (APP) [4, 51. These changes are generated by 
mediators secreted from mononuclear phagocytes. Many 
efforts have been made to identify these mediator molecules 
and to study their functions. Interleukin 1 (IL 1) was the first 
of these mediators which became available in a pure state and 
in large quantity by molecular cloning [6-111. More recently, a 
second monokine, cachectin/tumor necrosis factor a (TNFa), 
has been cloned and characterized [12-161. 
In previous studies we have investigated the biosynthesis and 
regulation of APP in vivo and in rat hepatocyte primary cul- 
tures [17-271. Conditioned media from rat Kupffer cells 
[23, 28, 291 and human monocytes [23,27,30-341 were able to 
induce APP synthesis in rat hepatocytes. It was therefore of 
great interest to identify the factor(s) responsible for the 
induction of APP in hepatocytes. As a first candidate we 
tested murine recombinant IL 1 for its potency to stimulate the 
synthesis of a2-macroglobulin (azM), a strong APP in the rat. 
Only a weak a2M induction was observed [26]. Moreover, a2M 
synthesis in rat hepatocytes was strongly stimulated by con- 
ditioned human monocyte media lacking any IL1 activity 
23, 271. From these findings it became evident that a factor 
different from IL 1 is involved in the induction of APP in rat 
hepatocytes. This is in good agreement with the observations 
made by other authors [31, 32,35,36]. Ritchie and Fuller [30] 
designated the APP-inducing activity distinct from IL 1 as 
hepatocyte-stimulating factor (HSF). 
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Recently, acute-phase protein-inducing activity was attributed 
to cachectidTNFa [33, 371. Since HSF is still poorly character- 
ized, the question arose whether or not HSF is identical with 
TNFa. 
In the present communication we show that recombinant 
human TNFa as well as TNFa produced by human peripheral 
blood monocytes does not induce changes in the synthesis of 
a2M, albumin, al-proteinase inhibitor (alPI) and al-acute- 
phase globulin (alAPG) in rat hepatocyte primary cultures. 
2 Materials and methods 
2.1 Chemicals 
~-[~~S]Methionine (46 TBq/mmol) was purchased from the 
Radiochemical Centre, Amersham, GB. Protosol was 
obtained from New England Nuclear, Boston, MA, and pro- 
tein A-Sepharose CL-4B from Pharmacia, Freiburg, FRG. 
RPMI 1640 medium and phenylmethylsulfonyl fluoride were 
from Serva, Heidelberg, FRG. Fetal calf serum was purchased 
from Gibco, Eggenstein, FRG. Penicillin and streptomycin 
were from Seromed, Berlin, FRG. Insulin, actinomycin D and 
crystal violet were obtained from Sigma, Deisenhofen, FRG. 
Kallikrein trypsin inhibitor (Trasylol") was generously sup- 
plied by Bayer AG., Leverkusen, FRG. Lipopolysaccharide 
derived from Salmonella typhirnuriurn was from Difco, 
Detroit, MI. Recombinant TNFa was generously supplied by 
BASF AG., Ludwigshafen, FRG. It contained less than 1.3 ng 
endotoxin per mg protein. Rabbit antisera containing poly- 
clonal anti-TNFa antibodies were generated by immunizing 
rabbits (New Zealand White) with recombinant human TNFa. 
A serum dilution of 1 : 2000 neutralized completely 10 ngiml 
recombinant TNFa in the TNFa cytotoxicity assay. 
2.2 Preparation of rat hepatocyte monolayers 
Suspensions of rat hepatocytes were prepared as previously 
described by Tran-Thi et al. [38]. After washing the cells with 
Krebs-Henseleit buffer they were suspended in a modified 
Waymouth medium [39] containing 10% fetal calf serum, 
50 Ulml penicillin, 50 pg/ml streptomycin and 1 VM insulin. 
The high insulin concentration was chosen because insulin has 
been shown to enhance cell viability [40] and to be required for 
monolayer formation of hepatocytes [41]. Furthermore, insu- 
lin is rapidly degraded by hepatocyte cultures at 37°C [42]. 
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Aliquots of 0.3 ml cell suspension (2.5 x lo5 cells) were added 
to 16 mm contour-bottom Falcon plastic tissue culture dishes 
(Falcon, Oxnard, CA). The dishes were incubated at 37 "C in a 
humid atmosphere of air : C 0 2  (95% : 5%) for 3 h. The plates 
were then washed with Krebs-Henseleit buffer and 0.3 ml cul- 
ture medium was added as described [43]. Confluent monolay- 
ers were formed after an overnight incubation at 37°C in a 
humid atmosphere of air : C02 (95% : 5%). The hepatocyte 
primary cultures consisted of more than 97% hepatocytes. The 
cultures were routinely controlled by microscopic examination 
prior to each experiment. 
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2.3 Labeling of hepatocytes 
RPMI 1640 medium was used for the radioactive labeling of 
the hepatocytes. Three hundred kBq of [35S]methionine was 
added to 0.3 ml of methionine-free culture medium for the 
labeling of proteins. After incubation at 37°C for 3 h,  the 
media were separated from the cells and centrifuged at 
12000 X g for 5 min and used for immunoprecipitation. 
2.4 Immunoprecipitation 
The preparation of antisera against rat azM, albumin, alPI 
and al-acute-phase globulin (alAPG) has been previously 
described [17, 19, 241. Immunoprecipitations were carried out 
in the presence of an excess of antibody. Hepatocyte medium 
containing 10' cpm of trichloroacetic acid (TCA)-precipitable 
radioactivity was added to 1 ml buffer A (20 mM Tris/HCl, 
pH 7.6, 0.14 M NaCl, 5 mM EDTA, 1% Triton X-100) con- 
taining 1 mM phenylmethylsulfonyl fluoride and 0.1 mg of 
kallikrein trypsin inhibitor. After addition of 5p1 of specific 
antiserum and incubation at 4 "C overnight, the antigen-anti- 
body complexes were bound to 7 mg (dry weight) of pro- 
tein A-Sepharose and washed four times with buffer A and 
twice with 50 m M  sodium phosphate buffer, pH 7.5. Elution 
was achieved by incubation with 0.1 M TrisMCl, pH 6.8, 5% 
2-mercaptoethanol, 5% sodium dodecyl sulfate and 10% gly- 
cerol at 95 "C for 5 min. The eluted proteins were analyzed by 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
[44] and subjected to fluorography according to Bonner and 
Laskey [45]. For the quantification of the radioactivity incor- 
porated into the different APP, the corresponding bands iden- 
tified by fluorography were cut from the gels, solubilized with 
Protosollwater (9 : 1, vlv) at 45 "C overnight and counted in a 
liquid scintillation spectrometer. 
2.5 Preparation of human monocytes and conditioned media 
Human mononuclear leukocytes were prepared from buffy 
coats of normal blood units by density gradient centrifugation 
[46]. Four x lo6 human mononuclear leukocytes/ml were incu- 
bated at 37°C in a humid atmosphere containing 5% COl for 
2 h in plastic culture flasks (Falcon 3024F) in RPMI 1640 
medium supplemented with 2% human serum. Nonadherent 
cells were removed by two washes with the above medium. 
The adherent cells were then reconstituted with the same 
medium, incubated for 24 h in the presence of 1 ng of 
lipopolysaccharide (LPS) per ml and the supernatants were 
harvested by centrifugation and filtration (Nalgene SCN, 
45 pm, NalgelSybron, Rochester, NY). Alternatively, adhe- 
rent cells were pre-incubated for 24 h in the absence of stimu- 
lant and then incubated with LPS for further 24 h. 
2.6 TNFa assay 
The cytotoxicity assay for TNFa was carried out on sensitive 
L929 mouse fibrosarcoma cells (2 x lo4 celld0.2 ml culture) in 
the presence of actinomycin D (2 pg/ml) in RPMI 1640 
medium containing 10% heat-inactivated fetal calf serum. The 
cultures contained serial dilutions of TNFa samples. After 
20 h of culture, the surviving cells were fixed and stained with 
crystal violet [0.5% crystal violet, 8% (v/v) formaldehyde 
(37%), 0.17 NaCl, 22.3% ethanol] for 15 min. Excess dye was 
washed off with water and the remaining dye solubilized in 
33% acetic acid. Absorbance was measured at 540 nm. Con- 
centrations of TNFa were determined by comparing the dilu- 
tions at which 50% survival was measured with a recombinant 
TNFa reference, kindly supplied by BASF AG. 
2.7 IL1 assay 
Supernatants of stimulated human monocytes and controls 
were assayed for IL 1 in the costimulation assay on C3HIHeJ 
thymocytes as described [47]. 
3 Results 
Rat hepatocyte primary cultures were incubated with different 
amounts of recombinant human TNFa ranging from 1 pg to 
10 pg per ml medium for 12 h at 37°C and proteins were 
labeled with [3sS]rnethionine. Three positive APP, azM, 
alAPG and alPI, known to show very strong, strong or weak 
increases during inflammation (reviewed in [3]) and the nega- 
tive APP albumin were immunoprecipitated from the media of 
hepatocytes incubated with TNFa. Fig. 1 shows that recom- 
binant TNFa did not affect the synthesis of any of the 4 
selected rat APP. Since we found murine recombinant IL 1 to 
be a weak stimulator of a2M synthesis in rat hepatocytes [26], 
we studied the combined action of IL 1 and TNFa, in order to 
test whether TNFa enhances IL1  activity. No synergistic 
effect of TNFa and IL 1 was observed (data not shown). Since 
recombinant TNFa may have properties different from the 
physiologically synthesized material, conditioned media from 
LPS-stimulated human monocytes containing TNFa were 
added to hepatocyte primary cultures. A concentration of 
0.5 ng TNFa/ml was determined in the monocyte media. 
As shown in Fig. 2A, last column, conditioned monocyte 
media stimulated a2M synthesis 25-fold and alAPG synthesis 
2.5-fold, whereas alPI did not change. Albumin synthesis was 
decreased by 60%. These changes in the syntesis of the four 
APP are quite similar to those observed in vivo during inflam- 
mation. Thus, the conditioned medium of human monocytes 
contains inflammatory mediators leading to the induction of 
APP synthesis. Addition of a neutralizing antibody to TNFa 
should abolish the acute-phase response, if TNFa present in 
the monocyte medium is indeed the inducer of APP synthesis 
in hepatocytes. We therefore pre-incubated the conditioned 
media with diffeent amounts of anti-TNFa prior to the addi- 
tion to hepatocytes. As shown in Fig. 2A,B, first 3 columns, 
no inhibition of the acute-phase induction was observed, 
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Figure 1. Effect of human recombinant TNFa on the synthesis of APP in rat hepatocyte primary cultures. Rat hepatocyte primary cultures were 
prepared as described in Sect. 2.2 and kept in culture for 5 days. As indicated in the figure, TNFa in different concentrations was added to the 
hepatocytes. The specific activity of the TNFa preparation was 2 x 10' unitdmg. As a control (Co) the medium (RPMI 1640,1% fetal calf serum) 
in which TNFa had been diluted was added to the hepatocytes. After incubation for 12 h, cells were labeled with [35S]methionine for 3 h. a,M 
(a), albumin (b), alPI (c) and a,APG (d) were immunoprecipitated from the hepatocyte media containing lo5 cpm of TCA-precipitable 
radioactivity and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fluorography. The radioactivity of the immunop- 
recipitated proteins was related to the total TCA-precipitable material. Data are means k SD of 3 different experiments. 
Table 1. TNFa activity neutralized by anti-TNFa 
Dilution of anti-TNFa 
1 : loo0 
1 :  loo 
1 :  10 
No addition 
Control antiserum 
TNFa activity 
(titer)') 
c2 
c2 
C 2  
16 
16 
a) Titers of TNFa activity are given as the reciprocal dilutions at 
which 50% survival was measured in the TNFa assay. 
although the antibody had neutralized TNFa activity com- 
pletely (Table 1). 
Since the conditioned medium from LPS-stimulated freshly 
prepared human monocytes contains IL 1 activity, we 
examined whether IL1 might be  responsible for the acute 
phase induction. It is known that human monocytes lose their 
capability to secrete IL 1 after pre-incubation for 24 h prior to 
LPS stimulation [4&50]. When conditioned media from pre- 
incubated and stimulated human monocytes were added to 
hepatocytes, the acute-phase induction was still observed, 
although slightly diminished (Fig. 2B). Addition of different 
amounts of anti-TNFa to the pre-incubated conditioned media 
also did not affect the APP-inducing capacity. 
0.6 
O'* i 
16' 10' 10' 0 
Figure 2. Effect of anti-TNFa on the synthesis of acute-phase proteins induced by conditioned media from human monocytes. Conditioned 
media from LPS-stimulated human monocytes 0-24 h (A) or 24-48 h (B) after preparation from human blood were incubated for 30 min at 
room temperature with different amounts of a monospecific antibody to human recombinant TNFa at the final concentrations indicated, The 
antibody-treated conditioned media were added to hepatocyte primary cultures. After incubation for 12 h, hepatocytes were labeled with 
[35S]methionine and the synthesis of a2M (a), albumin (b), alPI (c) and a,APG (d) was measured described in Sect. 2.4. The conditioned 
medium from freshly prepared monocytes (A) contained IL 1 (titer 64) in the thymocyte assay, while conditioned medium from pre-incubated 
monocytes (B) contained no detectable IL1 at all. 
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We conclude from these results that TNFa is not the main 
mediator of the acute-phase response in rat hepatocyte pri- 
mary cultures. Furthermore, it is evident that a mediator 
different from IL1 is present in conditioned media from 
freshly prepared as well as from pre-incubated human mono- 
cytes after LPS induction. 
4 Discussion 
At first sight, our finding that human recombinant TNFa is not 
involved in the induction of seveal APP in rat hepatocytes is in 
contrast to the observations of Perlmutter et al. [37] and Dar- 
lington et al. [33]. These authors described stimulation of com- 
plement factor C3, factor B and al-antichymotrypsin in 
HepG2 and Hep3B2 cells by human recombinant TNFa. 
However, several other APP such as complement factors C2 
and C4, aIPI, fibrinogen, al-acid glycoprotein, C-reactive pro- 
tein and haptoglobin did not respond to TNFa. For the nega- 
tive APP albumin Perlmutter et al. [37] observed a decrease in 
synthesis, whereas Darlington et al. [33] did not detect a 
change after addition of human recombinant TNFa to human 
hepatoma cells. Taken together, TNFa was found to induce 
only a very limited number of APP. 
Both groups used tumor cell lines for their experiments. 
Therefore, their data should be interpreted with reservation. 
Tumor cells, as dedifferentiated cells, may not be the ideal 
model system to study the regulation of APP synthesis. In our 
study we avoided the use of a tumor cell line. Since human 
hepatocyte primary cultures are hardly available, we have 
used rat hepatocyte primary cultures. In response to con- 
ditioned medium from human monocytes rat hepatocytes 
synthesize APP similarly to the rat liver in vivo during inflam- 
mation. Thus, it is unlikely that species specificity is responsi- 
ble for the lacking effect of human recombinant TNFa on rat 
hepatocytes. This view is supported by experiments of Tracey 
et al. [51] who found that human recombinant TNFa exerts a 
strong action in the rat. Recently, Smith et al. [52] described 
human and mouse TNFa to be active in heterologous cell 
systems, although the concentrations of TNFa needed were 
higher than in the homologous system. 
From the fact that human recombinant TNFa did not induce 
a2M, alAPG or alPI synthesis in rat hepatocytes, while con- 
ditioned medium from human monocytes was a potent 
stimulator, it must be concluded that TNFa is distinct from 
HSF. 
IL1 was reported to induce several APP in rat hepatocyte 
primary cultures. Previously we described a 2-fold stimulation 
of a2M synthesis by murine recombinant IL 1 [26]. Ramadori 
et al. [53] described the induction of serum amyloid A and 
factor B by murine recombinant IL 1 in vivo and in hepatocyte 
primary cultures from mice. Increases in the synthesis of al- 
antichymotrypsin, factor B and C3, but not C2, C4 and a tPI  
were observed in Hep3B cells upon addition of human recom- 
binant IL 1 [37]. Using HepG2 cells, Karin et al. [54] induced 
metallothioneine mRNA by recombinant murine IL1. As in 
the case of TNFa, Darlington et al. [33] reported that among 
several APP tested in Hep3B2 cells mouse recombinant IL 1 
induced only the synthesis of C3. In rat hepatocytes Fuller et 
al. [31] did not observe any stimulation of fibrinogen synthesis 
by murine recombinant IL 1. 
From the fact that some APP are inducible by IL 1, whereas 
others are not, it is evident that IL1  is not an universal 
mediator in APP induction. 
In this study we have presented data which shows that TNFa 
did not induce rat a2M synthesis, whereas conditioned media 
of human monocytes devoid of TNFa and IL 1 activities were 
still capable of stimulating a2M synthesis 10-fold. Thus, a fac- 
tor distinct from TNFa and of much higher potency than IL 1 
is involved in the induction of APP. 
We are grateful to H.  Wintersinger and K. Gyufko for their technical 
assistance and to H.  Gottschalk for her help with the preparation of the 
manuscript. 
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